Top Page
GlaxoSmithKline
(NYSE:GSK)
GlaxoSmithKline (GSK) vs. SPDR S&P 500 ETF (SPY)
GlaxoSmithKline Business Overview & Revenue Model
GlaxoSmithKline Key Performance Indicators (KPIs)
Breaks down revenue by different business segments, highlighting which areas drive the most sales and profitability, and indicating where the company might focus its strategic efforts.
The FlyGlaxoSmithKline Earnings Call Summary
GlaxoSmithKline Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 31.95B | 31.38B | 30.33B | 29.32B | 24.70B |
| Gross Profit | 23.18B | 22.33B | 21.76B | 19.77B | 16.53B |
| EBITDA | 11.62B | 6.67B | 9.08B | 8.60B | 6.49B |
| Net Income | 5.59B | 2.58B | 4.93B | 14.96B | 4.38B |
Balance Sheet | |||||
| Total Assets | 61.01B | 59.46B | 75.22B | 60.15B | 107.14B |
| Cash, Cash Equivalents and Short-Term Investments | 3.40B | 3.71B | 6.61B | 7.88B | 5.87B |
| Total Debt | 17.69B | 16.99B | 22.97B | 20.99B | 32.74B |
| Total Liabilities | 45.02B | 46.38B | 58.91B | 50.05B | 78.23B |
| Stockholders Equity | 16.35B | 13.67B | 17.01B | 10.60B | 20.39B |
Cash Flow | |||||
| Free Cash Flow | 5.82B | 3.57B | 6.26B | 6.75B | 5.30B |
| Operating Cash Flow | 7.14B | 6.55B | 7.89B | 8.16B | 7.95B |
| Investing Cash Flow | -5.72B | -1.23B | -2.40B | -10.88B | -1.78B |
| Financing Cash Flow | -1.59B | -4.73B | -6.07B | 2.05B | -7.59B |
GlaxoSmithKline Technical Analysis
GlaxoSmithKline Risk Analysis
GlaxoSmithKline Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £215.50B | 28.13 | 23.00% | 1.53% | 10.20% | 40.57% | |
71 Outperform | $187.49B | 22.84 | 96.65% | 3.00% | 11.03% | 65.22% | |
71 Outperform | $117.06B | 15.61 | 39.27% | 4.84% | 1.26% | ― | |
69 Neutral | $108.22B | -31.42 | 14.71% | 4.58% | -9.32% | 120.62% | |
67 Neutral | $104.08B | 28.75 | 37.19% | 3.41% | 5.97% | 128.66% | |
64 Neutral | $153.36B | 18.21 | 8.67% | 6.65% | 4.44% | 128.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
GlaxoSmithKline Corporate Events
On 19 March 2026, GSK announced that the U.S. Food and Drug Administration approved Lynavoy (linerixibat), an ileal bile acid transporter inhibitor, as the first medicine in the U.S. specifically indicated for cholestatic pruritus in adults with primary biliary cholangitis, a rare autoimmune liver disease. The decision, underpinned by positive phase III GLISTEN trial data and orphan drug designations, marks GSK’s first liver therapy approval, strengthens its position in hepatology just days after agreeing to license global rights to linerixibat to Alfasigma, and could significantly improve quality of life for PBC patients as regulatory reviews continue in Europe, the U.K., Canada and China.
The most recent analyst rating on (GSK) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On March 16, 2026, GSK plc reported that its Chief People Officer, Diana Conrad, acquired 12.430 American Depositary Shares in the company through participation in the GSK pension plan at a price of $54.41 per ADS on the New York Stock Exchange. The transaction, disclosed in a March 2026 filing with the U.S. Securities and Exchange Commission, reflects routine executive share acquisition under employee benefit arrangements and provides additional transparency to investors regarding management’s equity holdings.
The most recent analyst rating on (GSK) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 17 March 2026, GSK plc repurchased 732,112 of its ordinary shares, with prices ranging between 2,002p and 2,036p and a volume-weighted average price of 2,016.45p, acting via BNP Paribas under its non‑discretionary buyback agreement. The shares will be held in treasury, bringing total treasury stock to 251,176,615 shares, or 6.18% of voting rights, and leaving 4,064,994,150 shares in issue, a move that continues GSK’s ongoing capital management programme and marginally increases earnings per share for remaining investors.
Since the buyback programme’s start on 17 February 2026, GSK has bought 11,285,521 shares in aggregate, signalling sustained management confidence in the company’s valuation and balance-sheet strength. The updated total voting rights figure of 4,064,994,150 will be used by shareholders to assess whether they must disclose changes in ownership under U.K. transparency rules, underscoring the governance implications of the transaction for institutional investors and other major holders.
The most recent analyst rating on (GSK) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 13 March 2026, GSK reported that its US president, Maya Martinez-Davis, acquired a small number of notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The transaction, executed on the New York Stock Exchange at a price of $53.39 per ADS for 129.152 notional ADS, represents routine dealing by a senior executive and underscores ongoing alignment of management incentives with shareholder interests.
The notification, filed with the U.S. Securities and Exchange Commission on 17 March 2026, forms part of GSK’s regular disclosure obligations for transactions by persons discharging managerial responsibilities. While modest in scale, such reported dealings provide investors with additional transparency around executive exposure to GSK’s equity-linked instruments and the company’s approach to long-term compensation structures.
The most recent analyst rating on (GSK) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 16 March 2026, GSK repurchased 628,000 ordinary shares of 31.25 pence each through BNP Paribas at prices between 2,026p and 2,052p, with a volume-weighted average price of 2,035.82p, as part of its ongoing share buyback programme. The shares will be held in treasury, taking total treasury holdings to 250,444,503 shares, leaving 4,065,726,262 shares in issue and establishing total voting rights at the same figure, with 6.16% of voting rights now attributable to treasury shares under UK disclosure rules.
The latest transaction brings GSK’s cumulative purchases since 17 February 2026 to 10,553,409 ordinary shares, underscoring the company’s continued capital-return strategy and active balance-sheet management. By increasing treasury holdings and confirming the updated denominator for voting-right calculations, the buyback affects institutional and retail investors’ disclosure thresholds and slightly concentrates ownership among remaining free-float shareholders while signalling management’s confidence in the company’s valuation.
The most recent analyst rating on (GSK) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On February 20, 2026, GSK plc reported that Maya Martinez-Davis, President, US, acquired notional American Depositary Shares through the reinvestment of dividends in her GSK Executive Supplemental Savings Plan account. The single transaction, executed on the New York Stock Exchange at a price of $59.52 per ADS for 70.566 notional ADS, was disclosed on February 27, 2026, underscoring routine executive participation in the company’s equity-based compensation and savings programs.
This disclosure highlights continued alignment between GSK’s U.S. leadership and shareholder interests through exposure to the company’s ADS performance. While the transaction is relatively small in scale, such filings offer investors additional transparency into executive holdings and reinforce governance practices expected of a major foreign private issuer in the U.S. market.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 26 February 2026, GSK plc repurchased 545,000 of its ordinary shares at prices between 2,155p and 2,211p, with a volume-weighted average price of 2,186.88p, under its ongoing share buyback programme executed via BNP Paribas SA. The shares, which will be held as treasury stock, lift total purchases since 17 February 2026 to 3,706,000 shares and leave GSK with 4,072,555,332 voting shares in issue and 5.98% of its voting rights now held in treasury, information that helps investors assess dilution, voting power and the scale of the company’s capital return activity.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 26 February 2026, GSK announced that Japan’s Ministry of Health, Labour and Welfare accepted for review a new drug application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B. This represents the first global regulatory filing for the potential first-in-class therapy in a country where nearly one million people live with the disease and chronic hepatitis B remains a leading cause of liver cancer.
The filing is backed by positive Phase III B-Well 1 and B-Well 2 trial data, in which bepirovirsen plus standard of care achieved statistically significant and clinically meaningful functional cure rates versus standard care alone, with an acceptable safety and tolerability profile. The drug, licensed from Ionis and already granted SENKU designation in Japan as well as other expedited statuses globally, could materially strengthen GSK’s position in hepatitis B if approved, opening a new market opportunity and potentially reshaping the standard of care in a large, underserved patient population.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
GSK plc said on 26 February 2026 that China’s National Medical Products Administration has accepted its new drug application for linerixibat for priority review to treat cholestatic pruritus in patients with primary biliary cholangitis, a rare autoimmune liver disease. The oral IBAT inhibitor previously showed rapid, significant and sustained itch and sleep-related improvements versus placebo in the phase III GLISTEN trial, with a safety profile consistent with prior studies.
The move underscores GSK’s push into hepatology and could address a major unmet need in China, where around 280,000 people are affected by PBC and up to 89% experience cholestatic pruritus with few effective options. Linerixibat has orphan drug status in the US, EU and Japan, while parallel marketing reviews are under way in the US, EU, UK and Canada, positioning the asset as a potential first-in-class global therapy if approvals follow.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 25 February 2026, GSK plc repurchased 455,000 ordinary shares at a volume-weighted average price of 2,209.58 pence, as part of its ongoing share buyback programme executed through BNP Paribas. The shares will be held in treasury, lifting treasury holdings to 243,052,094 shares and leaving 4,073,100,332 shares in issue, which sets the new total voting-rights denominator and results in 5.97% of voting rights now represented by treasury shares.
Since the non-discretionary buyback agreement with the broker took effect on 17 February 2026, GSK has cumulatively bought 3,161,000 ordinary shares, signalling continued capital-return activity and active management of its share capital structure. The updated voting-rights figure provides clarity for investors monitoring disclosure thresholds under U.K. transparency rules and may influence institutional investors’ reporting and governance calculations.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 13 February 2026, GSK disclosed that Chief People Officer Diana Conrad acquired American Depositary Shares in the company through a GSK pension plan transaction on the New York Stock Exchange. The purchase, documented in a Form 6-K filed on 25 February 2026 with the U.S. Securities and Exchange Commission, highlights ongoing equity-based participation by senior management, aligning executive interests more closely with GSK shareholders.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 20 February 2026, GSK plc reported that non-executive director Dr Hal Barron acquired 64 American Depositary Shares in the company at a price of $59.52 each through his GSK 401(k) plan, following the reinvestment of dividends. The small director dealing, executed on the New York Stock Exchange and disclosed on 25 February 2026, marginally increases Barron’s equity exposure to GSK and provides routine transparency for investors on insider holdings in the biopharma group.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 24 February 2026, GSK plc repurchased 477,000 of its 31¼ pence ordinary shares on the London Stock Exchange and Cboe Europe venues at prices between 2,175p and 2,217p, with a volume-weighted average of 2,200.50p per share. The shares, acquired through BNP Paribas SA under a non-discretionary mandate, will be held in treasury as part of the company’s existing share buyback programme.
Since the buyback arrangement commenced on 17 February 2026, GSK has bought a total of 2,706,000 ordinary shares, signalling continued capital returns to shareholders and active balance sheet management. Following the latest transaction, GSK holds 242,597,094 shares in treasury, leaving 4,073,555,332 shares in issue and the same number of voting rights outstanding, with treasury holdings representing 5.96% of voting rights under UK disclosure rules.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 25 February 2026, GSK announced an agreement to acquire Canada-based 35Pharma Inc., a private clinical-stage biopharmaceutical company developing novel TGF-beta superfamily therapeutics, for $950 million in cash, subject to customary regulatory approvals in the U.S. and Canada. The deal brings into GSK’s portfolio HS235, an investigational activin signalling inhibitor that has completed phase I trials and is moving into studies for pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction, potentially enhancing GSK’s RI&I pipeline with a differentiated profile that may lower bleeding risk and deliver metabolic benefits in a rapidly growing PH market forecast to reach $18 billion by 2032.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 20 February 2026, GSK reported that non-executive director Dr Hal Barron acquired 2,007.552 notional American Depositary Shares in his Executive Supplemental Savings Plan through the reinvestment of dividends at a price of $59.52 per ADS. On the same date, SVP and Group General Counsel James Ford obtained 47.46 notional ADS under the same plan and pricing, highlighting routine dividend-related equity accruals for senior leadership but implying no change to GSK’s broader capital structure or strategic direction.
These transactions, disclosed in a Form 6-K filed on 24 February 2026, occurred on the New York Stock Exchange and reflect standard alignment of executive and board interests with shareholders through ongoing participation in company equity schemes. For investors, the filings are primarily a matter of regulatory transparency around management dealings, rather than indicators of a shift in GSK’s operational or financial outlook.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
On 23 February 2026 GSK repurchased 462,000 ordinary shares at prices between 2,184p and 2,213p, at a volume‑weighted average of 2,200.95p, via BNP Paribas under its existing share buyback programme. The shares will be held in treasury, bringing total treasury holdings to 242,120,094 shares, while shares in issue excluding treasury stand at 4,074,032,332, which is also the updated total voting rights figure for regulatory disclosure purposes.
Since the non‑discretionary arrangement with the broker began on 17 February 2026, GSK has bought back 2,229,000 shares in aggregate, with the treasury position now representing 5.94% of voting rights in accordance with U.K. disclosure rules. The latest transactions underscore the company’s ongoing capital‑return strategy and slightly enhance earnings per share and ownership concentration for remaining shareholders by reducing the free float over time.
The most recent analyst rating on (GSK) stock is a Hold with a $70.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.